VIRX

Viracta Therapeutics Stock Price

10.86
0.25 (2.36%)
Upgrade to Real-Time
Regular Market
10.86

Low
7.2701

52 Week Range

High
18.24

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Viracta Therapeutics Inc VIRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.25 2.36% 10.86 13:37:01
Open Price Low Price High Price Close Price Prev Close
10.52 10.49 11.065 10.61
Bid Price Ask Price Spread News
10.87 10.92 0.05 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
540 51,641 $ 10.71 $ 552,885 - 7.2701 - 18.24
Last Trade Time Type Quantity Stock Price Currency
13:37:33 18 $ 10.8701 USD

Period:

Draw Mode:

Viracta Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 402.83M 37.09M 37.00M $ - $ - -5.22 -2.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 0.20%

more financials information »

Viracta Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VIRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week10.121611.6510.121611.04135,5170.73847.3%
1 Month11.4112.7510.121611.45156,183-0.55-4.82%
3 Months11.5213.087.3310.97365,552-0.66-5.73%
6 Months16.7618.247.270110.52373,844-5.90-35.2%
1 Year16.7618.247.270110.52373,844-5.90-35.2%
3 Years16.7618.247.270110.52373,844-5.90-35.2%
5 Years16.7618.247.270110.52373,844-5.90-35.2%

Viracta Therapeutics Description

Viracta Therapeutics Inc is a clinical-stage, biomarker-directed precision oncology company focused on advancing new medicines for the treatment of virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma.


Your Recent History
NASDAQ
VIRX
Viracta Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.